Peptide Information

General Information of This Peptide
Peptide ID
PEP00076
Peptide Name
P-(A5G27)-FITC
Structure
Sequence
KRLVSYNGIIFFLR-NH2
Peptide Type
Linear
Receptor Name
CD44 antigen (CD44)
  Receptor Info 
PDC Transmembrane Types Cell targeting peptides (CTPs)
Formula
C83H133N23O17
Isosmiles
[H]NCCCC[C@H](N[H])C(=O)N[C@@H](CCC/N=C(\N)N[H])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO[H])C(=O)N[C@@H](Cc1ccc(O[H])cc1)C(=O)N[C@@H](CC(=O)N[H])C(=O)NCC(=O)N[C@]([H])(C(=O)N[C@]([H])(C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC/N=C(\N)N[H])C(N)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C
InChI
InChI=1S/C83H133N23O17/c1-11-48(9)67(81(123)106-68(49(10)12-2)80(122)102-61(40-51-25-17-14-18-26-51)76(118)99-59(39-50-23-15-13-16-24-50)74(116)98-57(37-45(3)4)73(115)95-55(69(87)111)28-21-35-92-82(88)89)104-65(110)43-94-71(113)62(42-64(86)109)101-75(117)60(41-52-30-32-53(108)33-31-52)100-78(120)63(44-107)103-79(121)66(47(7)8)105-77(119)58(38-46(5)6)97-72(114)56(29-22-36-93-83(90)91)96-70(112)54(85)27-19-20-34-84/h13-18,23-26,30-33,45-49,54-63,66-68,107-108H,11-12,19-22,27-29,34-44,84-85H2,1-10H3,(H2,86,109)(H2,87,111)(H,94,113)(H,95,115)(H,96,112)(H,97,114)(H,98,116)(H,99,118)(H,100,120)(H,101,117)(H,102,122)(H,103,121)(H,104,110)(H,105,119)(H,106,123)(H4,88,89,92)(H4,90,91,93)/t48-,49-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,66-,67-,68-/m0/s1
InChIKey
KPLRCZDIFWVGTF-NWDMPNHUSA-N
Pharmaceutical Properties
Molecule Weight
1725.121
Polar area
685.78
Complexity
1724.02498
xlogp Value
-3.8892
Heavy Count
123
Rot Bonds
61
Hbond acc
21
Hbond Donor
23
The Activity Data of This Peptide
Peptide Activity Information 1 [1]
Percentage of labeled cells 98%
Binding Affinity Assay
4T1-Luc and B16-F10 cells were collected after trypsinization of cell monolayers. Cells (5 105) were incubated in 3% BSA for 30 min at room temperature and then treated with 50 μg/mL of the FITC-labeled P-(A5G27) or P-(A5G27scrm) in 0.5 mL of PBS containing 1% BSA for 1 h at 4 °C or for 4 h at 37 °C. Cells were then washed twice with PBS, and the fluorescence intensity was analyzed by Guava easyCyte flow cytometer (EMD Millipore, excitation at 488 nm and emission at 525 nm).

   Click to Show/Hide
Experimental Condition 4T1-Luc and B16-F10 cells
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
P-(A5G27)-PTX [Investigative]
 PDC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Metastatic Tumor
Efficacy Data Median overall survival (mOS)
48.50 days
Administration Dosage 15 mg/kg PTX equivalent dose
Description
The median survival of mice in the P-(A5G27)-PTX treatment group was longer than in P-(A5G27scrm)-PTX, P-(A5G27), and free PTX-treated groups (48.50 vs 40.5, 43, and 45.5, respectively); however, differences were nonsignificant (Figure 6B).
In Vivo Model 4T1 tumor-bearing mice.
Obtained from the Model Organism Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Metastatic Tumor
Efficacy Data Survival rate
40%
Administration Time 7 days
Administration Dosage 15 mg/kg PTX equivalent dose
Description
P-(A5G27)-PTX prolonged mice survival in 7 and 20% relative to the survival rates of free PTX and nontreated mice, respectively (Figure 5).
In Vivo Model B16-F10 melanoma tumor-bearing mice model.
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Metastatic Tumor
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.058 ± 0.015 µM
Administration Time 72 h
Description
P-(A5G27)-PTX was ˜4-fold more toxic than the nontargeted P-(A5G27scrm)-PTX copolymer, suggesting a faster (receptor-mediated) internalization (Figure 4).
In Vitro Model Mammary carcinoma 4T1 cell CVCL_0125
References
Ref 1 CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors. Mol Pharm. 2018 Sep 4;15(9):3690-3699. doi: 10.1021/acs.molpharmaceut.8b00269. Epub 2018 Jun 29.